Table 3 Primary endpoint (pneumonia) in each subgroup

With rheumatoid lung

12.3% (10/81)

5.6% (4/71)

Receiving biologics

3.1% (8/257)

2.4% (6/253)

Receiving immunosuppressants

4.1% (3/74)

2.9% (2/70)

Receiving steroid (>5 mg/day of prednisolone)

3.9% (5/130)

2.6% (3/117)

With advanced stage

3.7% (9/246)

3.8% (9/239)